Detalhe da pesquisa
1.
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Virol J
; 21(1): 70, 2024 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38515117
2.
Slow Waning of Antibodies Following BNT162b2 as a Third Dose in Adults Who Had Previously Received 2 Doses of Inactivated Vaccine.
J Infect Dis
; 227(2): 251-255, 2023 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108092
3.
Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.
Clin Infect Dis
; 76(3): e299-e307, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675370
4.
Serological assays for differentiating natural COVID-19 infection from vaccine induced immunity.
J Clin Virol
; 170: 105621, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38056114
5.
Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
Nat Med
; 29(2): 348-357, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652990
6.
Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents.
Front Immunol
; 14: 1106837, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949953
7.
Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.
World J Pediatr
; 2023 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38085470
8.
COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition.
NPJ Vaccines
; 8(1): 151, 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37798293
9.
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Lancet Microbe
; 4(9): e670-e682, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549680
10.
Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases.
Kidney Int Rep
; 8(11): 2356-2367, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38025215
11.
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
Nat Med
; 28(3): 486-489, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35051989
12.
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents.
Nat Commun
; 13(1): 3700, 2022 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35764637
13.
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.
Signal Transduct Target Ther
; 7(1): 397, 2022 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36517469
14.
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.
Front Immunol
; 13: 982155, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36203563
15.
Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
Nat Med
; 30(1): 305, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875568
16.
Humoral and Cellular Immunogenicity and Safety of 3-Dose Inactivated COVID-19 Vaccine in Young Children Less Than 5 Years With Kidney Diseases.
Kidney Int Rep
; 8(10): 2177-2179, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850008
17.
Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents.
Nat Commun
; 13(1): 4798, 2022 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35970832